Актуальные новости из мира фармации и медицины, мнения экспертов, полезные советы и интересные факты.
🙋🏻♂️Вопросы: @zefal
🕵🏻♂️Реклама: @signato
https://www.gosuslugi.ru/snet/67a357ff4689c2151c6ae79a
Created
8 December 2017 — measured — cross-checked against a third-party dataset (ext.tg_channel)
Health & wellness — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 11 September 2026 and assigned it the closest of 31 fixed categories, at 86% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and the other topics.
Growth
27 measurements spanning 91 days, net -104. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 9,714–9,853 and does not start at zero.
Measurement log — every subscribers count we have recorded, most recent 20 of 27
Measured (UTC)
Subscribers
Change
5 Nov 2026, 14:56
9,733
+3
2 Nov 2026, 06:19
9,730
-1
30 Oct 2026, 00:15
9,731
-3
26 Oct 2026, 18:57
9,734
-6
23 Oct 2026, 15:56
9,740
-3
20 Oct 2026, 23:27
9,743
-2
18 Oct 2026, 02:38
9,745
-6
14 Oct 2026, 21:06
9,751
-4
11 Oct 2026, 21:57
9,755
-8
5 Oct 2026, 06:57
9,763
-12
27 Sept 2026, 04:37
9,775
-11
18 Sept 2026, 07:18
9,786
-4
14 Sept 2026, 12:19
9,790
-3
11 Sept 2026, 09:01
9,793
-5
6 Sept 2026, 13:37
9,798
-10
2 Sept 2026, 09:47
9,808
-2
30 Aug 2026, 08:36
9,810
-3
27 Aug 2026, 17:44
9,813
-12
24 Aug 2026, 14:17
9,825
+1
21 Aug 2026, 01:44
9,824
first reading
Engagement
30 posts held, back to 1 April 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 47 pages of Telegram’s post history, 20 posts per page.
ERR · 30 days
7.83%
avg views ÷ 9,733 subscribers
Avg views / post
762
5 posts measured
Reaction rate
0.919%
reactions ÷ views · ER floor
Posts in window
5
of 30 held
ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.
ER is defined industry-wide as (forwards + reactions + comments) ÷ views — note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.
What these figures were computed from
Window
Rolling 30 days · latest post in window 7 November 2026
Posts held
30 (1 April 2026 – 7 November 2026)
Views total
3,809
Reactions total
35
Forwards / comments
not exposed by the public surface — not measured, not estimated
Readings taken
7 Nov 2026, 22:26 UTC
Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.
Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.
Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.
What this channel posts
Photos
199
Videos
18
Links
575
Lifetime counters from Telegram’s own channel header, read 7 November 2026 — not the date at the top of this page, which is when the subscriber count was last read. Below Telegram’s rounding threshold, so these counts are exact.
Reaction mix
177 reactions across 29 posts, in 12 distinct kinds. The most used accounts for 31.1% of them.
Every reaction kind recorded on the sample, most used first
Reaction
Count
Share
Share, drawn
❤
55
31.1%
✍
35
19.8%
👍
31
17.5%
💊
24
13.6%
🔥
16
9.04%
👌
4
2.26%
🗿
4
2.26%
👏
3
1.69%
👎
2
1.13%
👀
1
0.565%
🤔
1
0.565%
🤨
1
0.565%
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 30 of the 30 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 188 reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 30 most recent posts we hold, published 1 April 2026 to 7 November 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
Recent posts
Telegram’s own ‘edited’ marker: 3 of 5 posts held from the last 30 days (60.0%) carried it when this register last read them. The marker says a post was changed after publishing, not what it said before — this register holds the earlier wording only where an edit fell between two of its own reads (see the edit ledger and how it is measured).
💬 Минздрав РФ разрешил клиническое исследование I фазы ZE74-0282 при миелопролиферативных новообразованиях
При миелофиброзе нарушается кроветворение в костном мозге, и арсенал терапии остаётся предметом активной разработки. Минздрав РФ разрешил международной компании Eilean Therapeutics провести в России исследование I фазы противоопухолевого препарата ZE74-0282. Препарат разрабатывают для лечения миелопролиферативн…
💬 FDA расширило применение равулизумаба при первичной IgA-нефропатии - пока речь только о снижении протеинурии
При первичной IgA-нефропатии иммунные комплексы повреждают почечные клубочки, а заболевание может привести к почечной недостаточности. Протеинурия отражает количество белка в моче и стала основой нового решения FDA. FDA применило ускоренную процедуру одобрения равулизумаба для взрослых с первичной IgA-нефро…
Обзор аптечных продаж противодиарейных препаратов от DSM Group
Розничные продажи противодиарейных препаратов (ATC-группа A07) в январе-июле 2026 года составили около 29 млрд рублей или 67 млн упаковок. Средняя цена упаковки достигла 432 рубля.
Структура спроса: 40% натурального объёма приходится на сорбенты, 26% – на закрепляющие препараты, 20% – на противодиарейные микроорганизмы, 11% – на противомикробные средств…
💬FDA одобрило Mimrylo (русфертид) при истинной полицитемии - первый препарат, имитирующий гормон гепсидин
При истинной полицитемии костный мозг производит избыток эритроцитов, кровь становится вязкой, растёт риск тромбозов, инсульта и инфаркта. Гематокрит стараются удерживать ниже 45%, и основной инструмент для этого - флеботомия. Но даже на фоне терапии части пациентов нужны частые процедуры.
FDA одобрило Mimrylo …
💬FDA одобрила Hibsago (bepirovirsen) при хроническом гепатите B - первый препарат нового класса
Обычная картина при хроническом гепатите B: человек годами принимает противовирусные таблетки, чтобы вирус оставался подавленным. Полностью «отпустить» терапию удаётся далеко не всем.
FDA одобрила Hibsago (bepirovirsen) - инъекционный препарат нового класса: антисмысловой олигонуклеотид. Он нацелен на генетические инстру…
Онлайн-продажи слабительных растут: рынок прибавил 20,7%
По данным DSM Group, в январе-июле 2026 года российский аптечный рынок слабительных препаратов достиг 30,6 млн упаковок на сумму более 14 млрд рублей.
По сравнению с аналогичным периодом прошлого года продажи выросли на 13,8% в деньгах и на 1,6% в натуральном выражении. В категории представлено около 200 SKU, объединенных 63 брендами.
🔝Наиболее заметная дина…
В России зарегистрирован оригинальный препарат для терапии рака яичников и HER2-негативного рака молочной железы
Минздрав России зарегистрировал препарат Элефуза® (МНН: фузулопариб) — оригинальный селективный ингибитор PARP1/2 для терапии распространённого эпителиального рака яичников, рака маточной трубы, первичного перитонеального рака и метастатического HER2-негативного рака молочной железы. Производить и поставл…
Упаковки решают: кто растет на сжимающемся рынке
✅ За семь месяцев 2026 года аптечный рынок лекарств достиг 1 177,8 млрд рублей – на 12% больше, чем за аналогичный период 2025 года. Однако в натуральном выражении продажи сократились на 3,2% - до 2 490 млн упаковок.
📊 Инфляция лекарств составила около 2,5%, причём весь рост обеспечен препаратами вне списка ЖНВЛП (+3,9%), тогда как цены на ЖНВЛП снизились на 0,5%.
Л…
💬FDA одобрила Lisraya (brepocitinib) - первый пероральный препарат для дерматомиозита у взрослых
Дерматомиозит - редкое аутоиммунное заболевание, при котором иммунная система атакует мышцы и кожу, вызывая хроническое воспаление, прогрессирующую мышечную слабость и характерные высыпания. Brepocitinib - ингибитор JAK/TYK2, принимается один раз в сутки.
➡️Регуляторное решение
• FDA выдала финальное одобрение Lisraya …
Розничная фарма: кто растет быстрее в 2026 году
📈По данным аналитической компании RNC Pharma, российский розничный рынок лекарств по итогам первых 7 месяцев 2026 года вырос на 11,3%, до 1,17 трлн рублей относительно прошлого года. При этом в натуральном выражении спрос снизился на 2,9% – до 2,72 млрд упак.
📊Всего на розничном рынке страны в январе-июле 2026 г. было представлено более 810 различных компаний, однако …
Моновитамины: 4,2 млрд рублей и новый лидер
Российский рынок «традиционных» небрендированных моновитаминов насчитывает 130 ассортиментных единиц от 55 производителей.
📊 По данным DSM Group, за 12 месяцев с июня 2025 г. по май 2026 г. в аптеках продано 31 млн упаковок на сумму более 4,2 млрд руб. В рублях рынок вырос на 8,6%, в упаковках сократился на 9,1%.
84% натуральных продаж приходится на водорастворимые витам…
💬 FDA одобрила Orzeyful (oveporexton) - первый препарат, воздействующий на биологию нарколепсии 1 типа
По данным агентства, это первый препарат, который напрямую восстанавливает сигналинг орексина и адресует полный спектр симптомов NT1 (нарколепсия 1-го типа), а не отдельные проявления заболевания.
Нарколепсия 1 типа - редкое хроническое нейропсихиатрическое расстройство сна; в США её распространённость оценивают п…
❤2✍1👍1💊1
Showing the 12 most recent of 30 posts we hold for @pharmrussia. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Posts recorded as deleted after publishing
We recorded 1 post on @pharmrussia as deleted — posts this register held that were missing from the channel’s public page on two separate reads, taken from different network addresses at least an hour apart.
A deletion is not wrongdoing. This register can see that a post it held is no longer on the channel’s public page, and when — not why. Expired ad placements, reposts, rotating links and corrections all look the same. This is a count of recorded detections, not an exact total: it misses deletions we could not see, because only a post we held and later re-read inside the page can be seen to go, and it may include a small number of wrong records. How this is measured.
First seen missing
5 November 2026
Most recent seen missing
5 November 2026
Median time before seen missing
15 days
Seen missing in the last 30 days
1
Mentions
Named by 1 registered channel — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.
Named by
Channels on the register whose posts name this channel's handle.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
Appears in Telegram’s recommendations for other channels
The reverse of the list above, and a different kind of signal. This does not require this channel to have ever been asked about directly — each row below is a channel we DID ask Telegram about, whose Telegram-generated list happened to include this one. A channel can appear here with an empty list above it, because being named by someone else’s query is independent of having been queried itself.
Наше здоровье | Блог Алексеева @nasche_zdor · 18,677 Telegram ranks this channel #9 of 76 here — alongside 75 others — read 5 October 2026
Подслушано | Аптека @podslushano_apteka · 23,867 Telegram ranks this channel #22 of 83 here — alongside 82 others — read 16 September 2026
This channel appears in 2 seed channels' Telegram-generated recommendation lists in total. Each is Telegram’s list for THAT channel, not this one — see how this is measured.
Cite this entry
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 5 November 2026 — this
entry's latest reading, not the date you are reading this.
“Первый лекарственный” (@pharmrussia), 9,733 subscribers as measured 5 November 2026. Telegram Register, tgregister.com/channel/pharmrussia.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.